OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Osborne on Pertuzumab in HER2+ Breast Cancer

April 25th 2017

Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Dr. Higano Discusses PARP Inhibitors in Prostate Cancer

April 25th 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses PARP inhibitors in prostate cancer.

Dr. Satapathy on Recurrence in Orthotopic Liver Transplant Recipients With HCC

April 25th 2017

Sanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.

Significance of Analyzing Gene Mutations in Prostate Cancer

April 25th 2017

Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.

Dr. Sangro Discusses Safety Profile of Nivolumab in HCC

April 25th 2017

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

Dr. Barber on Chemotherapy Versus Surgery for Ovarian Cancer

April 25th 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy versus surgery for patients with ovarian cancer.

Dr. Seiwert on Managing Side Effects for Head and Neck Cancer Treatment

April 25th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

Dr. McDermott on Immunotherapy-Related AEs in RCC

April 24th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

Dr. Farago on Combination of Olaparib and Temozolomide in Small Cell Lung Cancer

April 24th 2017

Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olarparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).

Dr. Kelley Discusses Biomarkers for Immunotherapy in HCC

April 22nd 2017

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma.

Dr. Bendell on Remaining Questions With Regorafenib in HCC

April 22nd 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the remaining questions researchers have with regorafenib (Stivarga) for patients with hepatocellular carcinoma (HCC).

Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer

April 22nd 2017

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Dr. Chase on Toxicities of Treatments for Ovarian Cancer

April 21st 2017

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologist oncologist with Arizona Oncology, discusses the toxicity profiles and managing side effects of treatments for patients with recurrent ovarian cancer.

Relationship Between OCT1 Expression and Poor Response to Sorafenib in HCC

April 21st 2017

Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the relationship between reduced organic cation transporter-1 (OCT1) and poor response to sorafenib (Nexavar) in hepatocellular carcinoma (HCC) and cholangiocarcinoma.

Dr. Slovin on the Future of Immunotherapy in Prostate Cancer

April 21st 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

Dr. Nambiar on Next Steps with Galectin-1 for Head and Neck Cancer

April 21st 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses the next steps with targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in patients with head and neck cancer.

Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck Cancer

April 21st 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

Dr. Parikh on the Optimal Frontline Therapy for Patients With CLL

April 21st 2017

Sameer Parikh, MD, hematologist, Mayo Clinic, discusses first-line therapy choices for patients with chronic lymphocytic leukemia (CLL).

Dr. Nowakowski on Evolving Treatment Paradigm of MCL

April 21st 2017

Grzegorz Nowakowski, MD, assistant professor of medicine, Mayo Clinic, discusses the evolving treatment paradigm of mantle cell lymphoma (MCL).

Dr. Usmani on Combining Daratumumab for Multiple Myeloma

April 20th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.